8.95
+4.445(+98.78%)
Currency In USD
| Previous Close | 4.5 |
| Open | 9.19 |
| Day High | 10.29 |
| Day Low | 8.61 |
| 52-Week High | 17 |
| 52-Week Low | 2.68 |
| Volume | 109.98M |
| Average Volume | 10.06M |
| Market Cap | 698.21M |
| PE | -2.76 |
| EPS | -3.24 |
| Moving Average 50 Days | 5.03 |
| Moving Average 200 Days | 8.82 |
| Change | 4.45 |
If you invested $1000 in Replimune Group, Inc. (REPL) since IPO date, it would be worth $590.04 as of October 21, 2025 at a share price of $8.945. Whereas If you bought $1000 worth of Replimune Group, Inc. (REPL) shares 5 years ago, it would be worth $216.01 as of October 21, 2025 at a share price of $8.945.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncoly
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
GlobeNewswire Inc.
Oct 19, 2025 12:00 PM GMT
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IG
Replimune Provides Update Following Type A Meeting with FDA
GlobeNewswire Inc.
Sep 18, 2025 1:15 PM GMT
WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meetin